{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2020"],"condition":["Colorectal cancer metastatic","Colorectal cancer stage IV"],"disease":["Colorectal Cancer Stage Iv","Colorectal Cancer Metastatic"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2540754"],"location":["Denmark"],"study_start_month":["12"],"keyword":["Irinotecan","Oxaliplatin","Calciumfolinate","Capecitabin","Fluorouracil"],"repository":["ECRIN MDR"],"study_status":["Ongoing"],"additional_accession":[]},"is_claimable":false,"name":"OPTIMISE: A study investigating if analysis of cancer DNA in blood can be used to guide adjuvant treatment in patients  with advanced colorectal cancer","description":"Primary objectives: The primary aim of the present study is thus to investigate – in a randomized trial – the clinical utility of circulating tumor DNA analysis to guide treatment decisions in oligometastatic colorectal cancer.\nPrimary endpoints: Rate of patients free from recurrent CRC at 2 years post local treatment","dates":{"creation":"2020-12-15"},"accession":"2540754","cross_references":{"EU Clinical Trials Register":["2020-004524-41"]}}